NCT05791838|Unknown
Experience in Borderline Ovarian Tumors
Borderline Ovarian Tumors: Results of a Retrospective, Single-center Experience
Loading search results
Borderline Ovarian Tumors: Results of a Retrospective, Single-center Experience
Sponsor study identifier
observational
86
0 countries
N/A
Study Start
March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Borderline ovarian tumors (BOTs) comprise 15-20% of primary ovarian neoplasms and represent an independent disease entity among epithelial ovarian cancers. The present study aimed to report the 8-year experience of a single center on the management and outcomes of consecutive BOTs patients. From January 2010 to December 2017, all patients with BOTs undergoing surgical treatment were included. Demographic, clinical, and pathological data were reviewed retrospectively.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
February 8, 2023
Actual (reported)March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
March 30, 2023
Actual (reported)Oncological outcome
Patients who underwent surgery for BOT
through study completion, an average of 1 year
Patients surgically treated for borderline ovarian tumors (BOT)
Basilio Pecorino, M.D.
University of Catania
Paolo Scollo, M.D. Ph.D.
University of Catania
Antonio Simone Laganà, M.D. Ph.D.
University of Palermo
Andrea Etrusco, M.D.
University of Palermo
First Submitted
February 8, 2023
First Posted
March 30, 2023
Study Start
March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Primary Completion
March 2023
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
March 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
March 30, 2023
Record last verified: 2023-03
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: